Walden Biosciences Announces Research Collaboration with World Renowned Genetic Epidemiologist to Advance Work on Causal Role of suPAR in Chronic Kidney Disease
May 13, 2024 07:00 ET
|
Walden Biosciences, Inc.
CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Walden Biosciences, Inc. (Walden), a private, venture-backed biotechnology company advancing disease-modifying therapies to transform the treatment...
Walden Biosciences Announces Positive Topline Data from Phase 1+ Clinical Study of WAL0921 in Development for Treatment of Kidney Diseases
April 15, 2024 07:00 ET
|
Walden Biosciences, Inc.
Proprietary Human anti-suPAR Monoclonal Antibody Demonstrated Safety and Reduction of Circulating Free suPAR, a Cause of Kidney Disease Plans to Initiate Phase 2 Basket Study in Glomerular Kidney...
Walden Biosciences Expands Research Collaboration with the University of Michigan
January 10, 2024 07:00 ET
|
Walden Biosciences, Inc.
Expands partnership with laboratory of world-leading physician-scientist, Salim Hayek, M.D. Includes biomarker analysis from Walden’s Phase 1+ clinical study with Walden’s humanized anti-suPAR...
Walden Biosciences to Host Virtual Event on November 14, 2023 “Transforming the Treatment Landscape of Chronic Kidney Disease”
November 07, 2023 07:00 ET
|
Walden Biosciences, Inc.
Virtual event to include overview of Walden’s development programs and fireside chats highlighting the CKD landscape with Key Opinion Leaders Webcast to begin at 11:00 AM EST CAMBRIDGE, Mass., Nov. ...
Walden Biosciences Announces First Subject Dosed in First-in-Humans Phase 1 Clinical Trial of WAL0921, in Development for Treatment of Chronic Kidney Diseases
June 05, 2023 07:48 ET
|
Walden Biosciences, Inc.
Trial to Evaluate Proprietary Human anti-suPAR Monoclonal Antibody for Safety, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers Expects to Complete Enrollment by Year End 2023 CAMBRIDGE,...
Walden Biosciences Promotes Curt Dewan, CFA to Chief Financial Officer
April 05, 2023 07:00 ET
|
Walden Biosciences, Inc.
CAMBRIDGE, Mass., April 05, 2023 (GLOBE NEWSWIRE) -- Walden Biosciences, Inc. (Walden), a private, venture-backed biotechnology company focused on transforming the treatment of kidney disease, today...
Walden Biosciences Announces Presentation at the Oppenheimer 33rd Annual Healthcare Conference
March 09, 2023 07:00 ET
|
Walden Biosciences, Inc.
CAMBRIDGE, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Walden Biosciences, Inc. (Walden), a private, venture-backed biotechnology company focused on transforming the treatment of kidney disease, today...
Walden Biosciences To Present at 5th Annual Chronic Kidney Disease Drug Development Summit
March 08, 2023 07:00 ET
|
Walden Biosciences, Inc.
CAMBRIDGE, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Walden Biosciences, Inc. (Walden), a private, venture-backed biotechnology company focused on transforming the treatment of kidney disease, today...
Walden Biosciences Announces Presentation at Antibody Engineering and Therapeutics Conference 2022
December 02, 2022 07:00 ET
|
Walden Biosciences, Inc.
CAMBRIDGE, Mass., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Walden Biosciences, Inc. (Walden), a private, venture-backed biotechnology company focused on transforming the treatment of kidney disease, today...
Walden Biosciences Announces Participation at October Investor Conferences
October 13, 2022 07:00 ET
|
Walden Biosciences, Inc.
CAMBRIDGE, Mass., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Walden Biosciences, Inc. (Walden), a private, venture-backed biotechnology company focused on transforming the treatment of kidney disease, today...